Our Trials

ADP-A2M10 Non-Small Cell Lung Cancer Clinical Trial

This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti- tumor activity of Adaptimmune's ADP-A2M10 (MAGE-A10) therapeutic candidate in patients who are HLA-A*02 positive and have advanced (Stage IIIb or Stage IV) or recurrent non-small cell lung cancer (NSCLC) that expresses MAGE-A10. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2M10 SPEAR T-cell therapy. Further details are available via the link below.

View Clinical Trial

Publications

Please visit our Publications page for more information on ADP-A2M10 (MAGE-A10)

Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

To learn more about Non-small cell lung cancer visit the Cancer Information page or click the link below.